The partnership between clinical leaders at Harvard and manufacturing experts at Landmark Bio aims to bridge the gap between laboratory breakthroughs and clinical-grade therapies. For infants born with complex congenital heart defects, the current medical standard often involves a harrowing series
Manufacturing failures can occur if patients receive lymphodepleting agents like bendamustine too close to the collection of their therapeutic T cells. This biological reality creates a high-stakes environment for oncologists managing relapsed/refractory multiple myeloma, where the timing of every
Regulatory hurdles and the complexity of characterizing nanoparticle behavior in humans have slowed the progress of bone-targeted nanomedicines. Despite these significant challenges, osteosarcoma remains a primary concern in pediatric oncology due to its high rate of metastasis and the persistent
Engineering a synthetic alternative to natural nerve grafts requires a complex balance of structural durability, nutrient diffusion, and precise biological signaling. When peripheral nerves are severed, the internal fibers often lose their way, leading to permanent loss of sensation and motor
The partnership builds upon existing initiatives like the Center for Bioenergy Innovation to ensure that sustainable materials are both discovered and manufactured domestically. This integration addresses the notorious valley of death where biological breakthroughs often fail to reach the market
Optimizing package design to improve medication adherence reduces environmental waste associated with failed clinical treatments and hospital readmissions. This realization has transformed the healthcare sector from a purely protective stance to one that views packaging as a critical component of
